Advanced Magnetics seeks new Feridex labeling
Contrast media developer Advanced Magnetics announced in late December its submission to the FDA of a supplemental new drug application for Feridex I.V. The application seeks an expansion of indications to include differentiation of liver lesions as
Contrast media developer Advanced Magnetics announced in late December its submission to the FDA of a supplemental new drug application for Feridex I.V. The application seeks an expansion of indications to include differentiation of liver lesions as benign or metastatic. The company also hopes to change the dosing regimen to allow more rapid infusion. Expanding the labeling for Feridex I.V. could make the MRI contrast medium more competitive, according to the company. The agent, which was originally approved by the FDA on Aug. 30, 1996, is being marketed in the U.S. by Berlex Laboratories, a subsidiary of Schering of Germany.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
